EICHORCondition: Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
To Evaluate the Efficacy and Safety of TQB3909 Tablets versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
This description comes directly from the study's public registry record.
Jian Yong Li, doctor · 13951877733 · lijianyonglm@126.com
Ke Shu Zhou, doctor · 13674902391 · dr_zkshu23810@163.com
Always discuss trial participation with your own doctor first.
| Henan Province | Zhengzhou, Henan, China | — |
| Jiangsu Provincial People's Hospital | Nanjing, Jiangsu, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07753369